Using metronomic temozolomide for patients with advanced neuroendocrine tumors who are unfit for standard treatments

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II interventional study evaluates the effectiveness of metronomic temozolomide chemotherapy in patients with advanced neuroendocrine neoplasms (NENs) who are considered unfit for standard systemic treatments. Conducted across multiple Italian centers, the study aims to assess progression-free survival, overall response rate, and quality of life among participants. Patients will receive oral temozolomide continuously in 28-day cycles, and their clinical features will be analyzed to determine the therapy's impact. The study will also explore the correlation between MGMT status in tumor tissue and clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 18 years.
2. Histologically proven diagnosis of low grade GEP-NENs (including morphology and ki67 in accordance with WHO 2019 classification), bronchial carcinoids (in accordance with the Travis classification), low grade of unknown primary sites NENs.
3. Advanced disease (unresectable locally advanced or metastatic).
4. ECOG performance status 2 and/or moderate medullary impairment (at least one of the following criteria: Hb concentration \<10-8 gr/dl; WBC \<3000-2000/mm3; platelets \<75000-50000/mm3; neutrophil count \<1500-1000/mm3); renal failure (eGFR o CrCl 30-59 ml/min - G2) and/or moderate liver failure (Child B 7-9) and/or severe comorbidities and/or \> 3 prior systemic antitumor therapies (apart from SSA).

   For all the parameters other than the above mentioned criteria n° 4 consider the following criteria (that must be associated with at least one of those above): absolute neutrophil count of ≥1.5×109/L, platelet count of ≥100×109/L, haemoglobin ≥9 g/dL, serum total bilirubin \<1.5 times the upper limit of normal (ULN) alanine aminotransferase (ALT), AST, or alkaline phosphatase levels ≤2.5 times the ULN (if known liver metastases ALT, AST, and ALP ≤3× the ULN), serum creatinine \<1.5 times ULN or creatinine clearance ≥60 mL/min as estimated by the Cockcroft-Gault formula
5. Functioning/non functioning.
6. Morphological progressive disease (CT scan or MRI).
7. Recovery from toxicities related to any prior treatments, adequate wash-out period from previous treatments.
8. Ability to swallow pills.
9. Fertile men should agree to use effective contraceptive methods up to 6 months after the last temozolomide intake and should be informed about the possible irreversible infertility related to temozolomide intake.

Exclusion Criteria:

1. Patients pretreated with temozolomide.
2. Are Women of Child-Bearing Potential (WOCBP) and men who are able to father a child, unwilling to use adequate contraception prior to trial entry, for the duration of trial participation and for at least 28 days 2 weeks after treatment has ended. Adequate methods of contraception and Women of Child-Bearing Potential; WOCBP childbearing potential who are nursing or are pregnant or do not agree to submit to pregnancy testing required by this protocol
3. Patients that did not sign written informed consent prior to admission into the trial that is consistent with International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP) guidelines and local law
4. Knowed active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA) and/or known Human Immunodeficiency Virus (HIV) carrier.
5. Patients treated with systemic therapies (chemotherapy, interferon-alpha, somatostatin analogues, molecular target therapies) within 1 month prior to screening visit
6. Hypersensitivity to the active substance or to any of the excipients, hypersensitivity to dacarbazine (DTIC), known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before study entry, pregnant or lactating females, patients on chronic treatment with valproic acid

Where it's running

• European Institute of Oncology, IEO, IRCCS
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Francesca Spada, MD, PhD — European Institute of Oncology (IEO), IRCCS, Milan (Italy)
• Study coordinator: Francesca Spada, MD, PhD
• Email: francesca.spada@ieo.it
• Phone: +390257489258

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Postprandial drop and frailty in older adults having planned noncardiac surgery

  This study tests whether a drop in blood pressure after meals and frailty predict low blood pressure after anesthesia starts in adults 65 and older undergoing planned noncardiac surgery.

  Recruiting Konya City Hospital · Konya, Konya · NCT07914920

• Frailty Training for Emergency Nurses in Morocco

  This trial tests whether a four-module training program helps Moroccan emergency nurses recognize and care for frail older adults in the ER.

  Recruiting Cadi Ayyad University · Safi, SAFI · NCT07892612

• Physical Function and Fall Risk in Older Adults in Lalín's Frailty Prevention Program

  This study will look at how physical function and fall risk change in people 70 and older who participate in a routine frailty and falls prevention program, by comparing assessments before and after the 8–12 week program.

  Recruiting University of Vigo · Lalín, Pontevedra · NCT07848802

• Home-based multicomponent exercise program for older adults with osteosarcopenia and frailty

  This study tests a home-based exercise program built on the Fogg Behavior Model to see if it improves frailty, muscle strength, physical function, bone density, and quality of life in adults aged 60–85 with osteosarcopenia and frailty.

  Recruiting at 2 sites Affiliated 2 Hospital of Nantong University · Nantong, Jiangsu and 1 other locations · NCT07845656

• VIVI-OLIVE: Multicomponent Exercise and Olive Oil for Older Adults at High Risk of Falls

  In adults 75 and older at high risk of falling, this study tests whether a 24-month plan of personalized exercise, Mediterranean diet guidance, and 60 mL of extra virgin olive oil daily can improve walking speed and reduce fall risk.

  Recruiting Fundacion Miguel Servet · Pamplona, Navarre · NCT07829484

• Frailty-focused prehabilitation before heart surgery

  This study tests a home-based, frailty-tailored prehabilitation program for adults 65+ waiting 5 weeks or more for heart surgery to see if it improves fitness, frailty, heart-related function, nutrition, inflammation, quality of life, and hospital outcomes.

  Recruiting The University of Hong Kong · Hong Kong · NCT07824700

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.